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a b s t r a c t
Objective: The aim of the study was to explore the association of serum AMH and Renalase with the risk
of preeclampsia thereby assessing them as screening tools, reducing the risk of gravid consequences of
preeclampsia.
Materials and methods: This cross-sectional study recruited n ¼ 95 pregnant women between 14 and 32
gestational weeks. They were categorized as a) women with gestational hypertension (n ¼ 45); b)
women with pre-eclampsia (n ¼ 20) and c) normotensive pregnant women (n ¼ 30) according to the
ACOG criteria. Anthropometrics data and blood and urine samples were collected. AMH and Renalase
levels were measured by ELISA assay.
Results: The mean age of study cohort was 27.3 ± 6.2 year and weight was 65.1 ± 14.1 kg. Blood pressures
were significantly higher in pre-eclamptic patients versus both the gestational hypertensive females and
controls (p < 0.05). AMH was found to be significantly higher in controls but no difference was observed
between gestational hypertensive and pre-eclamptic patients. No difference was seen for serum Renalase
among the three groups (p > 0.05). AMH showed a negative weak correlation with diastolic blood
pressure (r ¼ 0.272; p ¼ 0.008) that remained significant even after adjustment (r ¼ 0.236; p ¼ 0.023)
whereas Renalase did not show any difference (r ¼ 0.051; p > 0.05). Females with low levels of AMH
were 1.07 times at risk of developing hypertension even after adjustment for age and BMI (p < 0.05).
Conclusion: Low AMH levels may lead to hypertension in pregnancy suggesting a role in detecting
vascular diseases as well as its effect on ovarian aging. However, further research is required to establish
a causal relationship.
© 2019 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Preeclampsia (PE) is a maternal disorder and clinically defined as
combination of hypertension and proteinuria after 20th week of
pregnancy [1]. It effects 5e6% of pregnancies and is a major cause of
morbidity and mortality for mother and child [2]. It can also lead to
hemolysis, elevated liver enzymes, and low platelet count (HELLP)
syndrome [1]. Previously different screening tests were reported for
predicting many pregnancy related outcomes, such as maternal
serum placental protein-13 (PP-13), pregnancy-associated plasma
protein-A (PAPP-A) and maternal serum placenta growth factor [3].
It is important to note that both PE and cardiovascular disorders
share common risk factors such as chronic hypertension, obesity,
and insulin resistance. Furthermore, association between early
menopause and vascular disease has also been proved. Sub-fertile
women with reduced ovarian reserve, appear to have an increased
rate of vascular complications in a future pregnancy [4]. Similarly, in
women with premature menopause, assisted reproduction has a
similar vascular complication in pregnancy suggesting a link
between ovarian physiology and cardiovascular health [5].
The anti-Mullerian hormone (AMH) is a member of the tissue
growth factor beta superfamily. Main source of AMH is ovary but
placenta may also produce AMH [6]. In females, the production of
AMH correlates with rise in the number of growing ovarian follicles
[7]. AMH has been found to modulate ovarian response to follicular
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stimulating hormone (FSH) but with unknown mechanisms.
Furthermore, AMH receptors were also documented in other places
like uterus and breast, proposing its physiological role which are
not known at this time [8]. An interesting fact regarding AMH is
that it can be used to reliably predict ovarian reservoir as it is
produced by the granulosa cells of small antral and pre-antral
follicles. Serum level of AMH corresponds to the size of the pool
of these follicles in animalmodels as well as in the human ovary [9].
Evidence based studies show reduced AMH levels in pregnancies
complicated by hypertensive disorders [10]. Association of lower
levels of serum AMH with advancing maternal age have also been
documented previously [11]. Furthermore, advancing age is a risk
factor for adverse pregnancy outcomes such as stillbirth, pre-
eclampsia, gestational diabetes and gestational hypertension [12].
However, for pre-eclamptic pregnancies, discriminated results of
low or high AMH levels have been documented [13].
Renalase is an enzyme that degrades circulating catecholamines.
Human renalase is 342 amino acids long, and made up of a signal
peptide, an amine oxidase domain and FAD-binding region [14].
Renalase circulates in the blood in an inactive form called as pro-
renalase, which is secreted by kidney. Pro-renalase has no amine
oxidase activity, and it is converted to renalase by increased cate-
cholamines level and high blood pressure. Renalase decreases the
blood pressure by degrading the catecholamines including dopa-
mine, epinephrine and norepinephrine [15]. This cyclical activation
of renalase and the resultant degradation of catecholamines helps
control blood pressure in a normal individual [16]. Hence, renalase
seem to indirectly regulate the cardiac function by controlling the
sympathetic activity and blood pressure [17]. Additionally, ongoing
studies have revealed a strong link between renalase, hypertension
and ischemic heart diseases [18]. Li, X., et al. have observed that
restricted renal blood flow resulted in down regulation of renalase
and subsequent increase in catecholamine concentration [19].
Recently, some studies were conducted to accurately determine the
levels of renalase in PE and also to speculate its predictive role [20].
Yilmaz and group reported low renalase levels in pre-eclamptic
pregnancies relating to the decreased glomerular filtration rate
and kidney function which are crucial organs affected by PE [21].
Furthermore, interesting facts have been documented in previous
studies about renalase's expression in mouse gonads such as
expression in testes, oocytes, granulosa, interstitial and luteal cells of
ovary, showing a possible connection of its activity with reproduc-
tion [22,23]. The shared expression of both renalase and AMH and
their possible involvement in reproductive health urged us to
explore the possible role in pregnancy related disorders. To the best
of our ability, we were unable to find any research that studied
both biomarkers in any reproductive health malady including pre-
eclampsia. Keeping this in mind, we designed a study with the aim
to explore the association of serummarkers AMH and Renalasewith
the risk of preeclampsia in our population. We compared the levels
of both these markers with that of normotensive pregnant females
and pregnancy induced hypertensive females. The goal of our study
was to explore biomarkers that can be used as screening tools that
could potentially help reduce the risk of gravid consequences of
preeclampsia.
Materials and methods
This cross-sectional study was conducted at the Aga Khan
University in collaboration with Basic Medical Science Institute,
Jinnah Postgraduate Medical Center Karachi, Pakistan with the
approval from the concerned ethical committees (ERC-4523-BBS-
16 and F.2e81/GENL-2017-IRB/15107/JPMC). The study subjects
were selected via convenient random technique from the antenatal
clinics and also from the labor room of a tertiary care hospital in
Karachi, between the periods of January to December 2017.
Informed written consent was obtained from all participants of the
study. Women having history of any chronic systemic disease, such
as cardiovascular, urogenital, immunological, endocrinological and
renal disease were excluded. Women with previous history of
complication of pregnancy such as abortion, intra uterine fetal
demise, antenatal bleeding was also not included in the study.
A total of 95 pregnant women, between the gestational ages of
14e32 weeks, were categorized into 3 groups according to their
health status: Group I: women with gestational hypertension
(n ¼ 45); Group II: women with pre-eclampsia (n ¼ 20); Group III:
normotensive pregnant women (n ¼ 30). Pre-eclampsia was
diagnosed according to American College of Obstetricians and
Gynecologists (ACOG) criteria 2013 as sudden onset of high systolic
blood pressure (140 mmHg or more) or diastolic blood pressure
(90 mmHg or more) confirmed by two readings 4e6 h apart,
with ± proteinuria of 0.3 gm/l or1þ proteinuria on urine dipstick
in the absence of urine infection, after 20 weeks of gestation in a
previously normotensive woman. Gestational hypertension was
taken as blood pressure of 140/90 mmHg or greater at least two
readings 4 h apart, appears after 20 weeks of gestation without
proteinuria [24]. Patient data regarding maternal age, gestational
age (calculated by first trimester ultrasound), systolic and diastolic
blood pressure readings, weight and height for BMI calculation,
reproductive history and medical history was collected. During the
antenatal visit, 10 ml of maternal venous blood was collected,
serumwas separated by centrifugation at 4000 rmp for 15 min and
stored at 80 C until used for estimation of anti mullerian hor-
mone (AMH) and serum Renalase by commercially available ELISA
kits (cat number 10011 and G7203 from GloryScince Co. Ltd, USA).
Proteinuria was estimated through urine dipstick method. Statis-
tical software SPSS version 21.0 was used for data recording and
analysis. A descriptive statistical analysis of continuous variables
was performed. Statistical comparisons were performed by using
Mann Whitney-U-test for quantitative variables, chi-square or
Fisher exact test for categorical variables. Pearson correlation and
regression analysis were conducted to identify the correlation of
biomarkers with hypertension. In all statistical analysis only
p-value < 0.05 was taken as significant.
Results
The mean age of study cohort was 27.3 ± 6.2 year and weight
was 65.1 ± 14.1 kg. On average the women were between
25.25 ± 7.3 weeks of gestation (Table 1). Table 2 compares the
biophysical and biochemical variables of the cohort sub grouped
according to the ACOG criterion. Diastolic as well as systolic blood
pressures were significantly higher in pre-eclamptic patients as
compared to both the gestational hypertensive females and con-
trols (p < 0.05). Serum AMHwas found to be significantly higher in
Table 1
Descriptive statistics of the study cohort.
Variables Study Population
Mean ± SD n ¼ 95
Age (years) 27.3 ± 6.2
Weight (kg) 65.1 ± 14.1
BMI (kg/m2) 25.49 ± 5.26
Gestational age (week) 25.25 ± 7.3
Diastolic BP (mmHg) 90 ± 16.9
Systolic BP (mmHg) 136.78 ± 24.22
Serum Renalase (ng/ml) 24.58 ± 2.37
Serum AMH (ng/ml) 1.04 ± 1.6
Where: AMH is Anti Mullerian hormone. BP is blood pressure. Data
expressed as Mean ± S.D.
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controls but there was no significant difference while comparing
gestational hypertensive and pre-eclamptic patients. No signifi-
cance was found in the difference between serum Renalase among
the three groups (p > 0.05). Urine dipstick assay for protein showed
that 95% subjects with PE had high protein positivity in urine
sample whereas 88.9% of GDM-HTN subjects showed no protein in
urine.
AMH showed a negative weak correlation with diastolic blood
pressure (r ¼ 0.272; p ¼ 0.008) that remained significant even
after adjustment for age and BMI (r ¼ 0.236; p ¼ 0.023) whereas
Renalase did not show any difference (r ¼ 0.051; p > 0.05). Next
we applied binary logistic regression to estimate the odds ratio of
the effect of age and BMI on the serum AMH levels in predicting
hypertension during pregnancy. In both, the unadjusted as well as
adjusted mode for age and BMI results showed that females with
low levels of AMH were 1.07 times at risk of developing hyper-
tension (p < 0.05) (Table 3).
Discussion
Pre-eclampsia is considered to be the leading cause of maternal
and neonatal morbidity and mortality. Maternal cardiovascular
system, placenta and the fetus are susceptible to organ damage by
pre-eclampsia. Furthermore, womenwith a history of preeclampsia
are at an increased risk of chronic hypertension, diabetes mellitus,
ischemic heart disease, cerebrovascular disease, kidney disease,
thromboembolism, hypothyroidism and impaired memory [25].
AMH role as amarker of ovarian reserve and ovarian aging has been
well established by previous studies [26e29], however its role in PE
is still not well understood.
AMH levels have been used in detecting the role of vascular
diseases as a causative factor of ovarian aging, particularly in
women with past preeclampsia [30]. In turn, ovarian aging has
been recognized as a source of increase incidence of cardiovascular
disease (CVD) [31]. Moreover, detection of AMH receptors on
cardiac tissue proposes the linkage of AMHwith cardiac physiology
[32]. In our study, we found reduced levels of AMH in pre-eclamptic
and gestational hypertensive subjects thus signifying its role in
prediction of ovarian aging, which is a strong risk factor for
development of preeclampsia. Previous studies have shown similar
results with AMH levels found to be lower in pre-eclamptic patients
than in normal patients [33]. Low AMH levels were found to have a
moderate association with gestational hypertension, and women
with a history of preeclampsia along with low ovarian reserve
[10,30]. However, another study showed no difference in AMH
levels between women with preeclampsia and controls [13].
There was no significant difference in the mean Renalase levels
of the three groups in our study. These findings are not consistent
with those presented by Yilmaz et al. [21] who suggested that high
blood pressure in pregnant females were associated with low
serum Renalase levels. They also proposed a direct relation of
serum renalase with glomerular filtration rate and an inverse
relationship with blood pressure levels. Recent study by Stoumpos
et al. showed that reduced AMH levels could be a predictor of
preeclampsia in pregnant women with a history of renal disease
[34]. One of the possible explanations for the observed difference in
results could be attributed to the fact that we were unable to
measure and control for the glomerular filtration rate in our study
subjects. It might be possible that all women included in our study
had a glomerular filtration rate within normal range therefore had
normal circulating Renalase. A second explanation for this differ-
ence in findings could be that the participants in the ‘Gestational
hypertension’ and the ‘pre-eclampsia’ group were hypertensive for
only a fewmonths with little or no impact on their kidney function.
In comparison to the conclusions drawn by Yilmaz et al. and
Stoumpos et al., Wang et al. has stated that there was no correlation
in serum Renalase levels and high blood pressure or arterial stiff-
ness in the Chinese Han population with normal renal function
[35]. Although the authors excluded all cases of secondary hyper-
tension, their results were consistent with the results of ours.
Obesity is considered a risk factor for pre-eclampsia [36], being a
prime factor for development of hypertension, causes increased
sodium reabsorption through renal tubules [37]. Most of our sub-
jects were overweight according to the South Asian guidelines;
hence this finding supports the association of weight with hyper-
tension. Furthermore, obesity also seem to affect serum AMH levels
in women of reproductive age, and is also a cause of aneovulatory
cycles with abnormal uterine bleeding, endometrial hyperplasia/
cancer, infertility and other pregnancy complications such as
Table 2
Physical and Biochemical characteristics of study population stratified on the basis of blood pressure.
Controls n ¼ 30
Mean ± SD
Gestational hypertension n ¼ 45
Mean ± SD
Preeclampsia n ¼ 20
Mean ± SD
Age (year) 25.9 ± 5.3 27.2 ± 5.14 29.7 ± 9.1
Weight (kg) 67.2 ± 15.7 64.8 ± 14.8 66.2 ± 13.34
BMI (kg/m2) 25.66 ± 5.45 25.08 ± 5.30 26.18 ± 5.07
Gestational age 24.3 ± 6.4 26.47 ± 3.3 25.25 ± 5.9
Diastolic BP (mmHg) 73.0 ± 13.17 95.1 ± 13.4 104 ± 10.9*
Systolic BP(mmHg) 114.3 ± 15.01 143.4 ± 11.6* 155.5 ± 14.7*
Renalase (ng/ml) 23.31 ± 1.38 27.34 ± 0.77 21.08 ± 0.89
AMH (ng/ml) 1.62 ± 2.29 0.73 ± 1.29 0.85 ± 1.07*
Urine Protein
Absolute Count (%)
0 26 (86.7) 40 (88.9)* e
1þ 4 (13.3) 5 (11.1) e
2þ e 16 (80.0)*
3þ e e 4 (20.0)*
Where: AMH is Anti Mullerian hormone. Data expressed as Mean ± S.D and absolute count with percentage in parenthesis. MannWhitney U test and chi square test were used
to compare the difference between groups and p < 0.05 considered significant. * means in comparison with controls.
Table 3
Logistic regression analysis for AMH.
Variables Unadjusted p value Adjusted for Age and BMI p value
OR (95% C.I) OR (95% C.I)
AMH 1.076 (1.010e1.145) 0.023 1.073 (1.007e1.143) 0.029
Where: Anti mullerien hormone (AMH). p < 0.05 considered significant.
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miscarriage or preeclampsia [38]. Therefore, we conducted logistic
regression to assess the effect of age and BMI; females with low
levels of AMH were 1.07 times at risk of developing hypertension
even after adjustment for age and BMI (p < 0.05). Though we report
lower AMH levels and normal Renalase levels in pre-eclamptic fe-
males and its independent association with blood pressure, further
studies needs to be conducted to establish a causal relationship.
Conclusion
In our study population, hypertensive disorders of gestation and
ovarian aging were associated with low serum AMH levels, sug-
gesting that the biomarker has a role in detecting vascular diseases.
However, no inference can be drawn for the same regarding Serum
Renalase levels. Further work up is needed to establish a causal and
correlational relationship.
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